Liquidia Submits Amendment to Add PH-ILD Indication to Tentatively Approved NDA for YUTREPIA™ (treprostinil) Inhalation Powder

No new clinical data is required to add PH-ILD indication as per FDA correspondenceRecertified that YUTREPIA does not infringe any valid patents listed in the Orange Book for TyvasoPreparing for...

Related Keywords

Delaware ,United States ,America ,Roger Jeffs ,Jason Adair ,Us District Court ,York Heart Association ,United Therapeutics Corporation ,Drug Administration ,Liquidia Technologies Inc ,Liquidia Corporation ,Orange Book ,Napproved Drug Products ,Therapeutic Equivalence Evaluations ,United Therapeutics ,Patent Trial ,Appeal Board ,Chief Executive Officer ,New York Heart Association ,Functional Class ,Dry Powder Inhalation ,Liquidia Technologies ,Private Securities Litigation Reform Act ,Markets ,